权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Anti-HLA Antibody Activation of Endothelial Cells in Cardiac Transplantation

心脏移植中抗 HLA 抗体激活内皮细胞

基本信息

批准号：
7595938
负责人：
ELAINE F REED
金额：
$ 38.5万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-05-01 至 2011-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7595938
关键词：
1-Phosphatidylinositol 3-Kinase Acute Address African Allogenic Allografting Antibodies Antibody Activation Antibody Formation Antibody Specificity Apoptotic Arteriosclerosis Asians Binding Biological Assay Biopsy Biopsy Specimen Cardiac Cell Proliferation Cell Survival Cells Chronic Clinical Clinical Data Clinical Research Clinical Trials Clinical assessments Data Data Set Databases Development Early treatment Endothelial Cells Endothelium Enrollment Ensure European Event Exhibits Fibroblast Growth Factor 2 Fibroblast Growth Factor 8 Fibroblast Growth Factor Receptors Focal Adhesion Kinase 1 Genes Geographic Distribution Goals Graft Rejection Graft Survival Growth Factor Receptors HLA Antigens Hand Heart Transplantation Hispanics Human Immune response Immunoglobulin G Immunosuppression Incidence Injury Intravenous Immunoglobulins Isoantibodies Ligation MHC Class I Genes Mediating Mus Observational Study Outcome Parents Pathogenesis Pathology Pathway interactions Patients Phosphorylation Plasmapheresis Process Protein Kinase C Proteins Protocols documentation Public Health Randomized Research Research Personnel Resolution Ribosomal Protein S6 Ribosomal Protein S6 Kinase Risk Risk Factors Role Sampling Schedule Serum Severities Signal Pathway Signal Transduction Signaling Protein Site Smooth Muscle Smooth Muscle Myocytes Specificity Surface Testing Therapeutic Transplant Recipients Transplantation United States Up-Regulation Vascular Diseases Vascular Endothelial Cell abstracting base clinically relevant cohort experience follow-up heart allograft human FRAP1 protein improved in vivo insight isoimmunity novel novel diagnostics patient population paxillin programs prospective receptor expression response sample collection tool treatment strategy

项目摘要

DESCRIPTION (provided by applicant): Cardiac transplant recipients exhibiting a humoral immune response to the allograft demonstrate increased risk of antibody-mediated rejection and transplant arteriosclerosis. HLA class I and class II signaling pathways have been implicated in this process because ligation of class I and class II molecules by anti-HLA antibodies initiates intracellular signals in endothelial cells that synergize with growth factor receptors to elicit cell survival and cell proliferation. Activation of anti-apoptotic and cell survival machinery in endothelial cells is augmented when cells are exposed to low concentrations of anti-HLA antibodies. In contrast, treatment of endothelial cells with high concentrations of anti-HLA antibodies stimulates cell proliferation. This suggests that lower levels of anti-HLA antibody binding to HLA may be beneficial to graft survival by activating survival signaling pathways that promote graft accommodation. On the other hand, high levels of anti-HLA antibody binding may have a detrimental effect on graft survival by upregulating FGFR expression, stimulating cell proliferation and increasing risk for development of transplant arteriosclerosis. We believe these findings are clinically relevant and may explain differences in transplant outcome in cardiac transplant patients producing anti-donor HLA antibodies. The overall goals of this proposal are to elucidate whether the intracellular signaling events initiated by antibody ligation of class I and class II molecules are influenced by the specificity and concentration of the HLA antibody and to determine the clinical relevance of class I and II signaling pathways in cardiac transplantation. Patient samples to be used in the proposed research will be obtained from the "CTOT-05 Observational Study of Alloimmunity in Cardiac Transplant Recipients". The CTOT-05 study is a prospective, non-randomized, multicenter, observational clinical trial in cardiac transplant recipients. Under Aim 1, we will characterize the ability of anti-HLA class I and class II antibodies in sera from heart allograft recipients to mediate proliferative and/or cell survival signals in endothelial cells. The IgG fraction of the serum will be tested for its ability to transduce signals via MHC class I and class II molecules in donor and surrogate endothelial cells bearing the relevant HLA antigen(s). Under Aim 2 we will assess the expression of anti-HLA antibody induced protein phosphorylation, fibroblast growth factor receptors and anti-apoptotic proteins in clinical biopsy specimens from cardiac allografts with and without anti-HLA antibody production. Understanding the class I and class II signaling pathways in the context of antibody mediated rejection and transplant arteriosclerosis is of importance for the development of new diagnostic tools and therapeutic strategies to improve patient management and cardiac transplantation outcome. Relevance to Public Health: Studying anti-HLA antibody mediated signal transduction in samples from the CTOT-05 clinical trial will permit us to establish the importance of the class I and class II signaling pathways in cardiac transplant outcome. These studies will identify key signaling proteins mediating acute and chronic antibody-mediated rejection and may permit the development of new treatment strategies. This study will develop and test class I and class II antibody mediated signal transduction as reliable indicators of transplant outcome and provide insight into mechanisms underlying antibody mediated graft injury. (End of Abstract)

描述（由申请人提供）：